BioSpace News Archive

Avant-garde Health and Titanium Healthcare, LLC have partnered to enable health systems to improve patient care, as part of the Centers for Medicare & Medicaid Services’ (CMS’) Bundled Payments for Care Improvement Advanced (BPCI Advanced) initiative

Cirius Therapeutics, a clinical stage pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and metabolic diseases, announced today that it will present preclinical data supporting the importance of the unique mechanism of action of its lead drug candidate for NASH at The International Liver Congress

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, announced today that two clinical outcomes abstracts on SkinTE™ for the treatment of diabetic foot ulcers (DFUs) will be presented at the Diabetic Limb Salvage (DLS) Conference in Washington, DC being held on April 4-6, 2019.

According to new data released today, the Express Scripts SafeGuardRx® offering – the company’s first-to-market value-based programs for employers and health plans – improved patient engagement and increased medication adherence while reducing costs for some of the nation’s costliest therapies.

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced data highlights from six presentations showcasing technology advances in the company’s antibody-drug conjugate (ADC) platform and an immuno-oncology program at the American Association for Cancer Research (AACR) Annual Meeting 2019 being held March 29-April 3, 2019 in Atlanta.

Vaxart, Inc. announced the completion of dosing of the lead-in cohort in the Phase 1b bivalent norovirus vaccine clinical trial with its oral norovirus GII.4 vaccine.

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it has initiated COURAGE, an international Phase 3 trial to evaluate the safety and efficacy of vibegron for symptoms of overactive bladder (OAB) in men who are receiving pharmacological treatment for benign prostatic hyperplasia (BPH).

HID Global® announced that the European Molecular Biology Laboratory in Grenoble, France has selected HID’s radio frequency identification tags and its patented direct bonding technology for automated handling of biological samples at cryogenic temperatures of 196°C in liquid nitrogen.

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of 18mg and 27mg Methylphenidate Hydrochloride Extended-Release Tablets, indicated as a treatment for Attention Deficit Hyperactivity Disorder (“ADHD”). The current annual U.S. market for these two strengths of the product is approximately $505 million, according to Iqvia.

The nation’s leading medical flight charity Miracle Flights today announced a total of 722 commercial flights coordinated in February 2019 for critically ill children in need of life-changing medical treatment not available in their local communities—up 17 percent from February 2018’s flight count of 617 and nearly 31 percent from 552 flights coordinated in February 2017.